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Abstract
Background: Electrophysiological data suggest that cardiac KATP channels consist of Kir6.2 and
SUR2A subunits, but the distribution of these (and other KATP channel subunits) is poorly defined.
We examined the localization of each of the KATP channel subunits in the mouse and rat heart.
Results:  Immunohistochemistry of cardiac cryosections demonstrate Kir6.1 protein to be
expressed in ventricular myocytes, as well as in the smooth muscle and endothelial cells of
coronary resistance vessels. Endothelial capillaries also stained positive for Kir6.1 protein. Kir6.2
protein expression was found predominantly in ventricular myocytes and also in endothelial cells,
but not in smooth muscle cells. SUR1 subunits are strongly expressed at the sarcolemmal surface
of ventricular myocytes (but not in the coronary vasculature), whereas SUR2 protein was found to
be localized predominantly in cardiac myocytes and coronary vessels (mostly in smaller vessels).
Immunocytochemistry of isolated ventricular myocytes shows co-localization of Kir6.2 and SUR2
proteins in a striated sarcomeric pattern, suggesting t-tubular expression of these proteins. Both
Kir6.1 and SUR1 subunits were found to express strongly at the sarcolemma. The role(s) of these
subunits in cardiomyocytes remain to be defined and may require a reassessment of the molecular
nature of ventricular KATP channels.
Conclusions: Collectively, our data demonstrate unique cellular and subcellular KATP channel
subunit expression patterns in the heart. These results suggest distinct roles for KATP channel
subunits in diverse cardiac structures.
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Background
ATP-sensitive (KATP) channels are widely expressed in
both excitable and non-excitable tissue types throughout
the body. However, differences exist in the functional and
pharmacological properties of various KATP channels in
different tissues. This functional diversity of KATP channels
is also reflected in the cardiovascular system. KATP chan-
nels are abundantly expressed in ventricular myocytes,
where they are probably best characterized. These chan-
nels have a high unitary conductance, are inhibited by
ATP in the micromolar range, are blocked by glibencla-
mide (but not tolbutamide) and opened by pinacidil (and
not by diazoxide). KATP channels also exist in the coronary
vasculature, where they function to maintain basal coro-
nary blood flow [1]. KATP channels in the coronary smooth
muscle have a low unitary conductance (~30 pS) and are
blocked by glibenclamide and activated by KATP channel
openers and adenosine [2]. KATP channels exist in the cor-
onary endothelium [3], but their biophysical properties
remain largely unidentified. In addition to this diverse
distribution of plasmalemmal KATP channels in the heart,
KATP channels with unique biophysical and pharmacolog-
ical profiles are also believed to be expressed in the mito-
chondrial inner membrane [4].
KATP channels are increasingly well characterized at the
molecular level. In order to express a functional channel
that resembles native KATP channels in terms of their bio-
physical and pharmacological properties, a combination
of two types of subunits is necessary. It is now understood
that Kir6 subunits form a pore-forming structure through
which K+ ions transverse the membrane whereas SUR sub-
units assemble with the latter to modulate the channel's
function and to confer unique pharmacological proper-
ties to the channel complex [5,6]. Two genes each code for
the two known Kir6 subfamily members (Kir6.1 and
Kir6.2) and for the two known SUR members (SUR1 and
SUR2). Alternative splicing of SUR2 gives rise to at least
two functionally relevant isoforms (SUR2A and SUR2B)
with distinct pharmacological profiles [5]. It is widely
believed that ventricular KATP channels consist of the spe-
cific combination of Kir6.2 and SUR2A subunits and that
KATP channels in vascular smooth muscle consist of Kir6.1
and SUR2B subunits. This view is consistent with results
from gene targeting experiments, which demonstrate the
absence of functional sarcolemmal KATP channels in ven-
tricular myocytes from Kir6.2(-/-) mice and the coronary
abnormalities that develop in Kir6.1 and SUR2 null mice
[5]. Although they are powerful tools, gene knockout
approaches can overemphasize certain important aspects
of gene function and may overlook more subtle effects of
protein function and interaction. At first sight, these mod-
els do not adequately explain the reports of SUR1 mRNA
expression in the heart [7], or the observation that anti-
SUR1 antisense oligonucleotides inhibit KATP channels of
ventricular myocytes [8]. They also do not provide a func-
tional basis for the known expression of Kir6.1 mRNA and
protein in cardiac myocytes [9-12]. or explain the molec-
ular composition of the endothelial KATP channel. The
specific cellular and subcellular localization of proteins
can be used to predict their function. We therefore used
antibodies specific for each of the KATP channel subunits
to determine their cellular and subcellular localization in
the mouse and rat heart. Our results suggest distinct roles
for each of the KATP channel subunits in diverse cardiac
structures.
Results
Given the reports of expression of each of the KATP channel
subunits in the heart (see earlier), we performed immuno-
histochemistry and immunocytochemistry to determine
the cellular and subcellular localization of Kir6.1, Kir6.2,
SUR1 and SUR2 subunits in mouse and rat ventricle. To
this end, we stained frozen sections of cardiac ventricular
tissue as well as cardiac myocytes enzymatically isolated
from mouse and rat hearts. Where possible, we used dif-
ferent antibodies to the subunits to ensure that the stain-
ing pattern observed was specific.
Characterization of the antibodies used in this study
We performed Western blotting to determine the specifi-
city of the antibodies used in this study. Three different
anti-Kir6.1 antibodies (NAF-1, CAF-1 and C-16) all detect
a band that migrates with an apparent molecular size of
44 kDa in Western blotting of rat heart membrane frac-
tions (Fig 1). A 44 kDa band was also detected by the 78A
antibody (not shown). These antibodies did not cross-
react with Kir6.2, since they detected only Kir6.1 (and not
Kir6.2) in parallel experiments on cells transfected with
various KATP  channel subunit combinations (data not
shown, see also reference [13]).
Both the 76A and G-16 anti-Kir6.2 antibodies have previ-
ously been characterized and we demonstrated that they
specifically detect a ~38 kDa band in Western blotting of
Kir6.2 transfected cells and do not detect heterologously
expressed Kir6.1 protein [13,14]. Here we show that both
of these antibodies also detect Kir6.2 subunits as a ~38
kDa band in Western blotting of heterologously expressed
Kir6.2 protein or rat heart membrane fractions (Fig 1).
The anti-SUR1 antibodies specifically detect SUR1 protein
(170 kDa) in cell lysates of COS7L cells transiently trans-
fected with SUR1/Kir6.2 cDNA as well as in membrane
fractions obtained from mouse hearts [15]. In the cell lys-
tates from SUR2B/Kir6.2 transfected cells, the SUR2 anti-
body recognizes a specific band at 150 kD in transfected
cells only (Fig 1) and did not detect SUR1 (not shown).
Thus, each of the antibodies used in this study detected
proteins at the correct molecular size in Western blottingBMC Physiology 2005, 5:1 http://www.biomedcentral.com/1472-6793/5/1
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Characterization of the antibodies used in this study Figure 1
Characterization of the antibodies used in this study. Rat heart membrane fractions were separated on 8–12% denaturing 
PAGE and Western blotting was performed using Kir6.1 (NAF1, CAF-1 or C-16) or Kir6.2 (G-16 or 76A) antibodies. In other 
experiments, lysates of HEK293 cells stably transfected with Kir6.1/SUR2B, or lysates of COS7L cells transiently transfected 
with SUR1, SUR2A or SUR2B cDNAs, were separated with PAGE and respectively immunoblotted with anti-SUR2 (C-15) or 
anti-SUR1 (C-16) antibodies. Molecular size markers are indicted as appropriate.BMC Physiology 2005, 5:1 http://www.biomedcentral.com/1472-6793/5/1
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and did not cross-react non-specifically with other
proteins.
Kir6.1 localization in the murine heart
We used an immunohistochemistry approach to identify
the localization of Kir6.1 protein in cryostat sections of
mouse ventricles. We used three separate antibodies that
produced similar results (NAF-1, CAF-1 and C-16). We
also used another anti-Kir6.1 antibody (78A) but this
antibody did not perform well in these assays. A typical
result is shown in Fig 2A where Kir6.1 protein was ubiqui-
tously detected throughout the ventricle. Closer inspec-
tion shows that Kir6.1 protein is expressed in a sarcomeric
striated pattern in ventricular myocytes. This effect is more
pronounced in epicardial myocytes (left hand side of
panel A and Fig 2B). In the midmyocardium, a punctate
staining pattern is apparent (Fig 2C). This was observed in
over 50 different cryosections that we examined (also
observed with the CAF-1 antibody).
The cylindrical shape of the punctate structures in Fig 2C
is reminiscent of coronary blood vessels. We tested vari-
ous antibodies to find suitable markers for smooth mus-
cle- and endothelial cells in the coronary vasculature. We
found antibodies against smooth muscle α-actin to be a
good marker for coronary vessels (Fig 3A) typically having
diameters upwards of about 10 µm. We also tested an
antibody against the apical endothelial protein ICAM-2
and found the antibody to detect endothelial cells lining
the inner layer of coronary arteries (Fig 3B and 3C). Addi-
tionally, the anti-ICAM-2 antibodies stained a large
number of smaller vessel-like structures having diameters
typically smaller than 15 µm (average around 6–8 µm).
These smaller vessels apparently do not have an apprecia-
ble amount of vascular smooth muscle cells, as judged by
the lack of smooth muscle α-actin staining, suggesting
that they may be coronary capillaries (the possibility that
some of them may be pre-capillary arterioles with low
amounts of smooth muscle cannot be excluded). To
examine the localization of Kir6.1 in coronary blood ves-
sels, we co-stained mouse ventricle with NAF-1 anti-Kir6.1
antibodies and anti-ICAM-2 antibodies (a marker for the
vascular endothelium). As shown in Figure 2D, there is
clear correspondence between Kir6.1 staining and ICAM-
2 localization, suggesting high expression levels of Kir6.1
in the coronary vasculature.
Given the high sensitivity of the NAF-1 antibody, we were
able to perform a sub-cellular localization study of Kir6.1
protein in the mouse heart (Fig 4; this approach was not
possible with other antibodies, which produced less sen-
sitive staining). We co-stained a cryostat section with anti-
bodies against smooth muscle α-actin (A1), Kir6.1 (A2)
and the endothelial ICAM-2 protein (A3). An overlay of
these three images is shown in panel B. A higher magnifi-
cation of the area roughly represented by the boxed area
(panel C) demonstrates that Kir6.1 subunits are ubiqui-
tously expressed and are present in ventricular myocytes,
the coronary smooth muscle walls as well as in endothe-
lial cells. Of these cells types, the highest expression levels
appear to occur in the vasculature.
Kir6.2 localization in the murine heart
We used several antibodies against Kir6.2 subunits to
determine their cellular localization. Both the 76A and the
G-16 antibodies (Santa Cruz) gave similar results. The
W62 antibody developed by us [13] did not seem to stain
more than background and we therefore assumed this
antibody not to work in this assay. In terms of staining in
the vasculature, we detected Kir6.2 subunit expression
mainly in the endothelium (arrows in Fig 5A) and not in
smooth muscle (as judged by a lack of co-localization
with smooth muscle α-actin). Evidently, Kir6.2 subunits
were expressed in cardiac myocytes as well, as demon-
strated in Fig 5B. The staining occurs in a sarcomeric stri-
ated pattern in ventricular myocytes (distance interval of
roughly 2.2 µm). Although not as apparent as with Kir6.1,
there appears to be expression of Kir6.2 subunits in small
coronary blood vessels (10 µm or less). These structures
are also stained by Kir6.1 antibodies (arrows in Fig 5B and
5C), suggesting co-localization of Kir6.1 and Kir6.2 subu-
nits in small coronary blood vessels.
Localization of SUR subunits in murine heart
Using anti-SUR1 antibodies, we observed staining pre-
dominantly in cardiac ventricular myocytes (Fig 5D). The
lack of staining of either large or small coronaries suggests
that SUR1 subunits are not expressed in the coronary vas-
culature of the mouse heart (note the lack of co-localiza-
tion of SUR1 with smooth muscle α-actin). In contrast,
pan-SUR2 antibodies stain both ventricular myocytes in a
regular striated sarcomeric pattern as well as small coro-
nary blood vessels (Fig 5E and 5F). Note the lack of high
expression levels in larger coronary arteries (round struc-
ture in Fig 5F), demonstrating that expression of SUR2
subunits occurs predominantly in small coronary vessels
(less than 10 µm). In separate experiments, we did not
detect a particularly strong co-localization with smooth
muscle α-actin (not shown), ruling against the possibility
that SUR2 is strongly expressed in the smooth muscle cells
of larger coronary vessels.
Subcellular localization of KATP channel subunits in 
enzymatically isolated ventricular myocytes
Fixation and permeabilization procedures can affect the
outcome of immunocytochemistry experiments. We
therefore compared three different methods. Isolated car-
diac myocytes were (a) fixed with paraformaldehyde and
permeabilized with Triton X-100, (b) fixed and perme-
ablized in a single step by ice-cold methanol or (c)BMC Physiology 2005, 5:1 http://www.biomedcentral.com/1472-6793/5/1
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Immunohistochemistry demonstrating the regional distribution of Kir6.1 subunits in cryostat sections of the mouse ventricle Figure 2
Immunohistochemistry demonstrating the regional distribution of Kir6.1 subunits in cryostat sections of the mouse ventricle. 
A: The low magnification image demonstrates regional expression differences with more prominent myocyte staining apparent 
in the epicardium (left) than in the mid-myocardium (right). Image width is 750 µm. B and C: Higher magnification of the same 
slide shown in previous panel showing an epicardial (B) and midmyocardial section (C). The image widths are respectively 102 
and 96 µm. D: Double stained section of a midmyocardial section using NAF-1 anti-Kir6.1 antibodies (D1) and ICAM-2 anti-
bodies as a marker of endothelial cells. (D2). The image width is 119 µm. The secondary antibodies used were Cy-3 conjugated 
donkey anti-rabbit and Cy-5 conjugated donkey anti-rat F(ab')2 IgG fragments.BMC Physiology 2005, 5:1 http://www.biomedcentral.com/1472-6793/5/1
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subjected to a two-step protocol with paraformaldehyde
fixation followed by methanol fixation/permeabilization.
Typical results obtained with the anti-Kir6.2 (76A) anti-
body are shown in Fig 6. In general, we found methanol
fixation to preserve membrane staining but to cause a loss
of intracellular fluorescence (Fig 6A). Paraformaldehyde
fixation, in contrast, better preserved staining of intracel-
lular structures (Fig 6B). The two-step fixation protocol in
general gave similar results to paraformaldehyde fixation,
but the fluorescence intensity was generally much higher
and more clearly defined (Fig 6C). This may be due to bet-
ter preservation of protein antigenicity and/or improved
permeabilization (and hence improved antibody accessi-
bility). Our data are consistent with a recent report
describing the two-step protocol to better preserve the in-
vivo subcellular localization of proteins [16]. We conse-
quently used the two-step protocol for all subsequent
experiments to examine the subcellular localization of
KATP channel subunits.
The subcellular distribution of Kir6.1 and Kir6.2 subunits
in isolated mouse ventricular myocytes is shown in Fig 7A.
Kir6.2 subunits are expressed in a regular striated pattern
throughout the myocyte (A2). Kir6.1 subunits showed a
similar expression pattern (A1), with the exceptions that
(a) Kir6.1 expression appears to be more punctate and (b)
staining is more prominent at the myocardial surface.
Since we used antibodies developed in different species
(chicken anti-Kir6.1 antibody and rabbit anti-Kir6.2 anti-
body) we were able to detect both proteins in the same
myocyte with little cross-reactivity of the secondary anti-
bodies. Although there is some degree of overlap in the
subcellular expression of Kir6.1 and Kir6.2 subunits (yel-
low in A3), it is apparent that there are areas within the
Immunohistochemistry markers to distinguish between vascular smooth muscle and endothelial cells Figure 3
Immunohistochemistry markers to distinguish between vascular smooth muscle and endothelial cells. A cryosection of mouse 
heart ventricle was simultaneously stained with FITC-conjugated smooth muscle α-actin antibody (A) and an antibody against 
the apical endothelial membrane protein, ICAM-2 (B). The secondary antibodies to detect ICAM-2 was Cy-5 conjugated don-
key anti-rat (pseudo-colored red for clarity). Panel C is an overlay of the preceding two panels. The image width is 238 µm.BMC Physiology 2005, 5:1 http://www.biomedcentral.com/1472-6793/5/1
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cell that express Kir6.2 but not Kir6.1 subunits. Thus, the
possibility exists that these subunits may have different
functional roles within the ventricular myocyte. Similarly,
SUR1 and SUR2 subunits also have distinct subcellular
localizations. We consistently observed strong surface
staining with SUR1 antibodies (Fig 7B) whereas SUR2
antibodies diffusely stain throughout the width of the cell
in a sarcomeric repeating pattern (Fig 7C). To address the
question whether there is co-localization of any of the
KATP  channel subunits with mitochondria, we used
MitoTracker Red as a mitochondrial marker. We found
MitoTracker staining to dissipate during immunocyto-
chemistry protocols and co-labeling with KATP channel
antibodies was therefore not an effective strategy. Never-
theless, the pattern of MitoTracker staining that we
observed shortly after fixation (Fig 7D) was inconsistent
with predominant subcellular distribution of any of the
KATP channel subunits and we conclude therefore that KATP
channel subunits are not abundantly expressed in cardiac
mitochondria.
Triple stain immunohistochemistry of mouse ventricle demonstrating the distribution of Kir6.1 subunits in the coronary  vasculature Figure 4
Triple stain immunohistochemistry of mouse ventricle demonstrating the distribution of Kir6.1 subunits in the coronary vascu-
lature. The cryostat section was stained with antibodies against smooth muscle α-actin (A1), Kir6.1 (A2) and endothelial-spe-
cific ICAM-2 (A3). B:Overlay of the three panels shown in panels A. C: Higher magnification of the boxed area highlighted in 
panel B.BMC Physiology 2005, 5:1 http://www.biomedcentral.com/1472-6793/5/1
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Immunohistochemistry demonstrating the cellular distribution of the Kir6.2, SUR1 and SUR2 subunits in cryostat sections of  the mouse ventricle Figure 5
Immunohistochemistry demonstrating the cellular distribution of the Kir6.2, SUR1 and SUR2 subunits in cryostat sections of 
the mouse ventricle. A: Co-staining of mouse ventricular section with smooth-muscle α-actin (green) and anti-Kir6.2 antibod-
ies (Santa Cruz). The latter antibody was detected with Cy-5 conjugated donkey anti-goat IgG (blue). B and C: Double-stain-
ing with anti-Kir6.2 antibodies (Santa Cruz) and CAF-1 anti-Kir6.1 antibodies (detected with Cy-3 conjugated donkey anti-
chicken IgY (red). The image width of panel A is 109 µm and for panels B and C it is 89 µm. D: Co-staining of a midmyocardial 
section with anti-SUR1 antibodies (Cy3-conjugated donkey anti-goat secondary antibodies were used; shown in red) and FITC-
conjugated smooth muscle anti-actin antibodies (shown in green). E and F: Cryosections stained with a pan anti-SUR2 antibody 
(secondary antibody was Cy-3 conjugated anti goat IgG. The image widths for panels D-F respectively are 238, 238 and 88 µm.BMC Physiology 2005, 5:1 http://www.biomedcentral.com/1472-6793/5/1
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Effect of different fixation protocols on immunocytochemistry of ventricular myocytes Figure 6
Effect of different fixation protocols on immunocytochemistry of ventricular myocytes. Enzymatically isolated ventricular myo-
cytes were subjected to fixation protocols with (A) methanol, (B) paraformaldehyde or (C) sequential double fixation with 
paraformaldehyde followed by methanol. The primary antibody in all cases was against Kir6.2 subunits (76A) and the secondary 
antibody was Cy-3 conjugated donkey anti-rabbit IgG. The image widths are respectively 137, 107 and 139 µm.BMC Physiology 2005, 5:1 http://www.biomedcentral.com/1472-6793/5/1
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Experiments were designed closer to examine the subcel-
lular expression of SUR1 subunits relative to Kir6 pore-
forming subunits (Fig 8). There was a remarkable degree
of co-localization of SUR1 subunits with Kir6.1 subunits
(Fig 8A) but not with Kir6.2 subunits (Fig 8B).
We finally examined the subcellular expression patterns of
KATP channel subunits in another species. We chose rat
ventricular myocytes for this purpose. We essentially
obtained the same results as with mouse myocytes. Using
different antibodies against Kir6.1 (NAF-1 and C16) we
observed strong surface expression of this subunit with a
smaller degree of intracellular labeling (Fig 9A and 9B).
SUR1 antibodies also strongly labeled the cell surface (Fig
9C). In contrast, Kir6.2 and SUR2 antibodies both labeled
repetitive patterns at sarcomeric distances (Fig 9D and
9E). Furthermore, there is strong co-localization of Kir6.2
and SUR2 subunits in ventricular myocytes (yellow in Fig
9F).
Discussion
Antibodies used in this study
A significant strength of our study is that we extensively
characterized the antibodies used. We performed Western
blotting with membrane fractions obtained from the
heart to ensure that a band of the expected size is detected.
Immunocytochemistry of isolated mouse ventricular myocytes demonstrating the subcellular localization of Kir6.1, Kir6.2,  SUR1 and SUR2 subunits Figure 7
Immunocytochemistry of isolated mouse ventricular myocytes demonstrating the subcellular localization of Kir6.1, Kir6.2, 
SUR1 and SUR2 subunits. A: Double staining of a ventricular myocyte with the CAF-1 anti-Kir6.1 antibody (A1) and 76A anti-
Kir6.2 antibody (A2). Panel A3 is an overlay of panels A1 and A2. Secondary antibodies used were Cy-3 conjugated donkey 
anti-chicken IgY (red) and Cy-2 conjugated donkey anti-rabbit IgG (green). Yellow in panel C demonstrates areas of co-locali-
zation. The image width is 91 µm. B: Ventricular myocyte probed with anti-SUR1 antibodies and detected with Cy-3 conju-
gated donkey anti goat secondary antibodies. Image width is 148 µm. C: Staining with a pan-SUR2 antibody (detected with Cy-
2 conjugated donkey anti-goat IgG). The image width is 229 µm. D: An isolated myocyte was stained with MitoTracker Red 
(500 nM) before being paraformaldehyde fixed and viewed with confocal microscopy Image width is 47 µm.BMC Physiology 2005, 5:1 http://www.biomedcentral.com/1472-6793/5/1
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Subcellular localization of Kir6.1, Kir6.2 and SUR1 subunits in ventricular myocytes Figure 8
Subcellular localization of Kir6.1, Kir6.2 and SUR1 subunits in ventricular myocytes. A: Co-staining of a mouse ventricular myo-
cyte with antibodies to Kir6.1 (A1: NAF-1) or SUR1 (A2: C-16). The secondary antibodies were Cy2-conjugated donkey anti-
rabbit and Cy3-conjugated donkey anti-goat. The degree of co-localization after background elimination is depicted in panel A3 
by plotting pixel intensities of the two channels against each other. Pseudo-coloring of pixels indicates degree of co-localization 
(black is low and white high). B: Co-staining of a mouse cardiac myocyte with anti-Kir6.2 antibodies (76A) and anti SUR1 anti-
bodies. Secondary antibodies used were Cy-2 conjugated donkey anti-rabbit to detect Kir6.2 (green) and Cy-3 conjugated don-
key anti-goat IgG to detect SUR1 (red). A 3-D reconstruction was performed (58 stacked images with a voxel size of 0.23 
µm3). The image width is 119 µm. The images shown on the bottom and right insets are cut-through projections of the cell 
width (the regions of cross-sections areas shown by the white lines; the middle of each image is also indicated by a white line 
for clarity).BMC Physiology 2005, 5:1 http://www.biomedcentral.com/1472-6793/5/1
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Further, we chose antibodies that showed little cross-reac-
tivity with other proteins, as judged by the absence of
non-specific bands. In as far as it was possible we used dif-
ferent antibodies to the same KATP channel subunits in
immunostaining experiments to ensure that the same
cellular and subcellular distribution staining patterns
occurred. Although not shown, we always performed neg-
ative controls to ensure that no staining was observed
when the primary antibodies were omitted (to eliminate
non-specific staining by the secondary antibodies used) or
that staining could be blocked by preincubation of anti-
body with the peptide to which the antibody has been
raised. Further, we used the primary antibodies at the low-
est concentrations possible to eliminate possible non-spe-
cific cross-reactivity with other proteins. Our study is a
comprehensive description of the cellular and subcellular
expression patterns of KATP channel subunits in the heart
given our stringent criteria and the panel of antibodies
available to us.
Expression of Kir6.2 and SUR2 subunits in ventricular 
myocytes
Sarcolemmal KATP channels in ventricular myocytes have
been described more than two decades ago [17]. Cardiac
sarcolemmal KATP channels have been described to consist
of hetero-octameric complexes of Kir6.2 and SUR2A sub-
units [5,18,19]. This concept was based on the similarities
in the biophysical and pharmacological characteristics
Subcellular localization of KATP channel subunits in isolated rat ventricular myocytes Figure 9
Subcellular localization of KATP channel subunits in isolated rat ventricular myocytes. A: Staining with NAF-1 anti-Kir6.1 anti-
bodies (detection with Cy-3 conjugated donkey anti rabbit). Image width is 128 µm. B: Staining with a different anti-Kir6.1 anti-
body (C16, Santa Cruz); secondary antibody used was Cy-3 conjugated donkey anti-goat IgG. Image width is 136 µm. C: 
Staining with an anti-SUR1 antibody. Image width is 128 µm. D: Co-localization of Kir6.2 and SUR2 subunits. The preparation 
was co-stained with an anti-Kir6.2 antibody (76A; detection with Cy-2 conjugated donkey anti-rabbit IgG; green) and SUR2 
antibodies (detected with Cy-5 conjugated donkey anti-goat IgG; pseudo-colored red for clarity). Panel D3 is an overlay of pan-
els D1 and D2; yellow is indicative of co-localization. Image width is 125 µm.BMC Physiology 2005, 5:1 http://www.biomedcentral.com/1472-6793/5/1
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when comparing heterologously expressed Kir6.2/SUR2A
channels with native cardiac KATP channels [20] and also
because of the known expression of Kir6.2 and SUR2A
mRNA and protein in the heart. Our data demonstrate
both Kir6.2 and SUR2A subunits to be expressed in ven-
tricular myocytes. Furthermore, we find that these two
subunits co-localize, which is consistent with the
biochemical, functional and pharmacological data sup-
porting the concept that they can combine to form a heter-
omeric channel complex [5]. Our data are also in
agreement with the finding that knockout mice deficient
of Kir6.2 or SUR2 subunits lack KATP channels in the ven-
tricular myocyte [21,22]. It is interesting that Kir6.2/SUR2
subunits are expressed in a regular striated pattern in ven-
tricular myocytes. Furthermore, close inspection of the
images shows that both Kir6.2 and SUR2 expression is
somewhat punctate. These observations are in complete
agreement with previous studies describing the expression
of SUR2 isoforms in the t-tubules and sarcolemma [23]
and the subcellular localization of sarcolemmal KATP
channels as determined by functional microscopy. Scan-
ning ion conductance (patch clamp) microscopy data
have demonstrated KATP channels to be organized in small
clusters and to be anchored in the Z-grooves (t-tubular
openings) of the sarcolemma [24]. Collectively, these data
suggest that KATP channels are predominantly expressed in
the t-tubular system. The implications of KATP channels
present in the t-tubular system are not entirely clear. Since
t-tubular ion channels may control action potential
propagation into the cardiac myocyte, it may be possible
for KATP channels to have a role in the spread of excitation
and action potential duration, particularly during condi-
tions of metabolic impairment when these channels are
more prone to opening. A shorter action potential dura-
tion in the t-tubular system would imply less Ca2+ entry at
the local control sites of SR Ca2+  release and hence
reduced contractility, which may in part explain the nega-
tive inotropic effects observed with KATP channel openers
[25]. However, the picture may be more complex since
both Kir6.1 and SUR1 subunits are also expressed in ven-
tricular myocytes.
Expression of Kir6.1 and SUR1 subunits in ventricular 
myocytes
We found clear expression of Kir6.1 and SUR1 subunits in
cardiac ventricular myocytes. Interestingly, both of these
two subunits are strongly expressed at the sarcolemmal
surface, but their functions in the sarcolemma are cur-
rently not understood. Since ventricular KATP channels can
be recorded in hearts from knockout mice lacking Kir6.1
subunits [9], it appears that Kir6.1 subunits are not an
absolute requirement for the formation of functional ven-
tricular KATP channels. It may be possible for Kir6.1 subu-
nits to have a role in the pathophysiological setting, as
demonstrated by the upregulated Kir6.1 expression levels
during cardiac remodeling after ischemia or hypoxia
[11,26]. To our knowledge, cardiac KATP channels have not
been studied in SUR-/- mice. However, SUR1 antisense
oligonucleotides inhibit KATP channels in rat ventricular
myocytes [8], suggesting a functional role for these subu-
nits in ventricular sarcolemmal KATP channel function.
Our data, demonstrating that both Kir6.1 and SUR1 sub-
units exhibit strong sarcolemmal expression, may require
a reassessment of the molecular composition of ventricu-
lar KATP channels during normal and pathophysiological
conditions.
Expression of Kir6 and SUR subunits in mitochondria
The concept has evolved that KATP channels are expressed
in the mitochondrial inner membrane and that these
channels are involved in the protection of the heart
afforded by ischemic preconditioning [27,28]. The molec-
ular nature of mito-KATP channels remains to be identi-
fied. There are almost as many reports describing the
presence of Kir6.0 subunits in cardiac mitochondria
[23,29,30]. as there are denouncing their existence in
these organelles [31,32]. We did not observe strong local-
ization of KATP  channel subunits in ventricular
mitochondria. However, the technique of immunocyto-
chemistry does not have sufficient resolution to rule out
the existence of KATP channel subunits in mitochondria
and our data therefore do not add significantly to this
debate, other than demonstrating that KATP channel subu-
nits are not abundantly expressed in mitochondria of ven-
tricular myocytes.
Expression of KATP channel subunits in the coronary 
smooth muscle
A tight coupling exists between metabolic status in the
heart and coronary blood flow. KATP channels have been
identified in several different vascular tissues, including
the coronary vasculature [33]. KATP channels in coronary
resistance vessels have also been implicated in
physiologically important stimuli such as regulation of
basal vascular tone, autoregulation of blood flow,
hypoxia-induced coronary vasodilation, reactive hypere-
mia (a clinical index of coronary reserve) and ischemia
(reviewed in [33,34]).
Molecularly, the identity of coronary smooth muscle KATP
channels has been characterized less extensively than the
KATP channels in cardiomyocytes. A recent study employ-
ing in situ hybridization histochemistry examined Kir6.1
and SUR2B mRNA expression in different vascular beds,
including the coronary vasculature [35]. Strong mRNA
expression of these two subunits was found in coronary
resistance arteries. Interestingly, Kir6.1/SUR2B expression
was not found in coronary veins or venules. We found
expression of Kir6.1 and SUR2B protein in primary
human coronary artery smooth muscle cells and cryosec-BMC Physiology 2005, 5:1 http://www.biomedcentral.com/1472-6793/5/1
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tions of human ventricle [13]. The present study is the first
systematic and comparative characterization of KATP chan-
nel subunit expression in the intact coronary vasculature.
We find Kir6.1 expression in blood vessels of different
sizes, including large vessels such as the aorta and large
arteries, but also in small resistance arterioles (as defined
by their diameter of larger than 12–15 µm and the pres-
ence of a well-defined smooth muscle layer). Without
using specific markers, we were not able to distinguish
objectively between venules and arterioles, but we did
occasionally observe vessels with a thin smooth muscle
layer (possibly veins or venules) that only expressed
Kir6.1 faintly (if at all). Collectively, our data using vari-
ous anti-Kir6.1 antibodies generally suggest that Kir6.1
subunits are expressed in coronary arterial smooth mus-
cle, and possibly to a lesser extent in coronary veins. In
contrast, we did not observe any staining of the coronary
smooth muscle with anti-Kir6.2 antibodies.
We found strong staining of smaller coronary resistance
vessels with the anti-SUR2 antibodies. We did not have
access to suitable SUR2 isoform-specific antibodies, but
the staining most probably reflects SUR2B expression.
Curiously, we failed to see strong SUR2 expression in
larger coronary arteries. This result is in apparent contra-
diction to the description that SUR2B mRNA expression
occurs in larger coronaries [35] and the lack of KATP chan-
nels in the aortic cells of the SUR2 knockout mouse [36].
Reasons for this discrepancy are unclear, but may relate to
the lack of sensitivity of the anti-SUR2 antibodies used,
thus underestimating SUR2 protein expression in other
structures. We did not observe SUR1 protein expression in
the coronary smooth muscle. Our data are therefore in full
support of the notion that KATP channels in coronary
artery smooth muscle (particularly the smaller resistance
vessels) are comprised of Kir6.1/SUR2 subunits (most
likely the SUR2B isoform).
Expression of KATP channel subunits in the coronary 
endothelium
The evidence that endothelial KATP channels play a role in
regulation of coronary blood flow is compelling.
Endothelial KATP  channels, for example, contribute to
shear stress-induced endothelial release of the vasodilator
nitric oxide in rabbit aorta [37] and may also mediate
vasodilation in response to hyperosmolarity or acidosis in
the coronary microvasculature [38,39]. Furthermore, the
powerful vasodilatory effect of adenosine may also be
mediated (at least in part) by endothelial KATP channels by
stimulating the release of nitric oxide from the endothe-
lium [40].
In the present study, we used immunohistochemistry
approaches and identified Kir6.1, Kir6.2 and SUR2
protein in the endothelium lining coronary vessels (Fig.
4) as well as in coronary capillary endothelium (as
defined by their small size of less than 10 µm, the pres-
ence of the endothelial marker ICAM-2 and the absence of
vascular smooth muscle). Our data are supported by pre-
vious studies. Using RT-PCR techniques, it has been estab-
lished that guinea pig coronary endothelial cells express
Kir6.1, Kir6.2 and SUR2B subunits [41]. The presence of
Kir6.1 and SUR2B mRNA also detected in the coronary
endothelium using in situ hybridization histochemistry
techniques [35]. Recently, using a combination of RT-PCR
and Western blotting techniques, we also identified
Kir6.1, Kir6.2 and SUR2B mRNA and protein expression
in primary human coronary artery endothelial cells [13].
Importantly, in the latter study we used co-immunopre-
cipitation approaches to demonstrate that native human
coronary endothelial KATP  channels are heteromeric
Kir6.1/Kir6.2 complexes in combination with SUR2B sub-
units [13]. Thus, the biophysical nature, modes of regula-
tion and functional consequences of these heteromeric
KATP channels in the endothelium may differ fundamen-
tally from homomeric KATP channels found in other tis-
sues. The investigation of endothelial KATP channels is
currently the subject of some of our ongoing studies.
Reservations
For this type of study, the specificity of antibodies used is
always a concern. To overcome this problem, we used
multiple different antibodies where possible and
obtained similar staining patterns. However, we only had
access to a single antibody to each of the SUR subunits
and consequently we have not been able to verify the spe-
cificity of these antibodies by comparing different anti-
bodies to each other (as we have done in the case of the
Kir6 subunits). Furthermore, we did not have access to
antibodies to the various splice variants of SUR1 or SUR2
and our data therefore do not address the possibility of
regional expression differences. A definitive study will
require the use of tissues obtained from knockout animals
(i.e. the immunostaining should be unequivocally absent
in tissues from knockout animals). Viable knockout ani-
mals for each of the proteins under consideration have
been generated, but we have not been able to obtain these
animals (or tissues from these animals) for this purpose.
Therefore, although we have taken every step possible to
minimize non-specificity issues, our results should be
interpreted within this limitation.
Conclusions
Our study is a comprehensive analysis of the various KATP
channel subunits in the heart. We found each of the KATP
channel subunits to be expressed in ventricular myocytes,
but with varying expression patterns. The roles of Kir6.1
and SUR1 subunits in ventricular myocytes remain to be
elucidated and may require a reassessment of the molecu-
lar nature of the cardiac KATP channel. Coronary smoothBMC Physiology 2005, 5:1 http://www.biomedcentral.com/1472-6793/5/1
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muscle expresses predominantly Kir6.1 and SUR2 subu-
nits, whereas the coronary endothelium expresses Kir6.1,
Kir6.2 and SUR2 subunits. Thus, there is wide diversity of
KATP channel subunit expression within the heart which
determines the functional responses of various cell types
to physiological and pathophysiological demands.
Methods
Immunohistochemistry
Adult mice were sacrificed by pentobarbital overdose and
the hearts were rapidly removed. All animal experiments
were approved by the institutional Animal Care Review
Board. Hearts were perfused at 37°C through the aorta
(Langendorff mode) with Tyrode's solution (in mM: NaCl
137, KCl 5.4, HEPES 10, CaCl2 1.8, MgCl2 1, NaH2PO4
0.33; pH adjusted to 7.4 with NaOH) containing pinacidil
(100 µM) to cause maximal vasodilatation as to clear the
vasculature of blood. Hearts were fixed by switching the
perfusate to paraformaldehyde (4% in phosphate-buff-
ered saline (PBS), pH adjusted to 7.4) for 15 minutes at
room temperature. The heart was incubated in 4% para-
formaldehyde overnight at 4°C. Following fixation, the
tissue was incubated overnight at 4°C in 30% sucrose in
PBS. The tissue was then embedded in M1 embedding
matrix (Thermo Shandon, Pittsburgh, PA) and placed on
dry ice until frozen. The block containing the tissue was
sectioned using a cooled (-20°C) cryostat (Microm Cryo-
Star HM 560, Kalamazoo MI) at 15 µm thicknesses. The
sections were transferred to Superfrost Plus slides (Fisher
Scientific) for further processing.
Tissue sections were allowed to warm to room tempera-
ture. The staining protocol was carried out in a moist
chamber to avoid dehydration. Blocking was performed
for 60 min with Tris-buffered saline (TBS; in mM 137
NaCl, 50 Tris, 2.7 KCl, pH 7.4) containing 4% goat or
donkey serum (depending on the secondary antibody
being used) and 0.2% Triton X-100 at room temperature.
The slides were incubated overnight at 4°C with primary
antibodies (see below) diluted in TBS containing 0.1%
serum and 0.2% Triton X-100. Double or triple immun-
ofluorescent studies were carried out by incubating the tis-
sue sections with more than one primary antibody at the
same time. Sections were washed three times for 15 min
each in TBS, and incubated with fluorescently labeled sec-
ondary antibodies (see below) for 1 h at room tempera-
ture. The samples were again washed three times for 15
min each in TBS. Sections were drained by blotting with
filter paper and a drop of mounting medium (containing
an anti-fade reagent) was added to the slides before
mounting with a standard coverslip. The mounting
medium was allowed to dry before the slides were imaged
using a Leica PS2 confocal microscope equipped with an
Argon 488 nm gas laser and Helium Neon lasers (543 and
633 lines). Most images were obtained using an emission
pin hole of 1.1–1.6 AE with either a 20× (0.7 NA) or a 63×
(1.2 NA) oil objective.
Isolation and immunocytochemistry of cardiac myocytes
Single ventricular myocytes were isolated from adult rats
or mice using previously described procedures. Briefly,
adult animals were sacrificed and the heart was rapidly
removed and perfused in Langendorff mode (at 37°C) for
sequential 5 min periods with Tyrode's solution and nom-
inally Ca2+-free Tyrode's solution (same composition, but
without the addition of CaCl2). Myocytes were dispersed
using collagenese (Sigma type I; Sigma-Aldrich Chemical
Corp, St. Louis, MO, USA) and proteinase (Sigma type
XXIV). The ventricles were removed and chopped into
small pieces and digested using Ca2+-free Tyrode's solu-
tion containing the same enzymes. Single dissociated
myocytes were plated onto laminin (10 ug/cm3)-coated
glass coverslips and incubated at 37°C for 15 min to allow
attachment to the coverslips before being fixed. In some
experiments, myocytes were incubated with 500 nM
MitoTracker Red 580 (Molecular Probes, Eugene, OR)
during this period.
Three different fixation protocols were employed. Some
myocytes were fixed in paraformaldehyde (4%) for 15
min at room temperature, whereas with others fixation
and permeabilization was performed in a single step by
incubation with ice-cold 100% methanol for 5 minutes at
-20°C. However, in the majority of the myocytes pre-
sented in this study a two-step fixation protocol was used
[16], in which myocytes were first fixed with paraformal-
dehyde (as described above) followed by methanol fixa-
tion/permeabilization. Irrespective of the fixation
method, myocytes were then washed with Ca2+ and Mg2+-
free PBS (Invitrogen, Carlsbad, CA). Myocytes were then
incubated with 0.1% Triton X-100 (in PBS) for 15 min at
room temperature, which permeabilizes surface mem-
branes as well as those of intracellular organelles (this step
was omitted when fixing the cells only with methanol but
was included in the two-step fixation protocol). Following
washing (2 × 5 min) and blocking (5% goat serum in PBS;
2 × 10 min) the cells were incubated with primary anti-
bodies (1 h at room temperature), washed (3 × 10 min in
PBS-serum) and incubated with secondary antibodies (45
min at room temperature). Following 4 washes (with PBS;
10 min each) coverslips were mounted and viewed using
confocal microscopy.
As a negative control, the primary antibody was adsorbed
with the peptide against which it was made (when availa-
ble). Negative staining controls (not shown) also
included a null control, in which the primary antibody
was omitted, which tested for non-specific staining of the
secondary antibody. To avoid background from second-
ary antibodies alone, we normally pre-blocked the tissueBMC Physiology 2005, 5:1 http://www.biomedcentral.com/1472-6793/5/1
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with 5% normal serum from the same host species as the
labeled secondary antibody. We used labeled secondary
antibodies that have been pre-adsorbed against mouse
and human and we titrated the labeled secondary anti-
body to obtain a maximal signal-to-noise ratio.
Transfection of cells
The coding regions of Kir6.1 and Kir6.2 (a gift from Dr. S.
Seino, Kobe University Graduate School of Medicine,
Japan) were subcloned into pcDNA3. HEK-293 or COS-
7L cells were cultured in D-MEM (Invitrogen) supple-
mented with 10% heat-inactivated fetal bovine serum and
20 µg/mL gentamycin. Cells were co-transfected according
to the manufacturer's recommendations (Fugene 6, Roche
Applied Science, Indianapolis, IN) with Kir6.1 or Kir6.2
cDNA (obtained from Dr S. Seino), SUR1 (Dr J. Bryan,
Baylor College of Medicine, Texas) or SUR2A cDNAs (a
gift from Dr Seino). Cells were lysed 48 h post-transfec-
tion.
Preparation of mouse heart membrane fraction
Adult Sprague Dawley rats were anesthetized and the
hearts were rapidly removed. Membranes were prepared
essentially as described before [42]. The protein content
was determined and equal amounts of proteins were sub-
jected to Western blotting.
Western blotting
Cells were solubilized in lysis buffer [25 mmol/L Tris, 150
mmol/L NaCl, 5 mmol/L EDTA, 1% (v/v) Triton X-100,
0.5% (w/v) deoxycholate, pH 7.5 supplemented with a
cocktail of protease inhibitors (Sigma)]. After centrifuga-
tion (10 min at 16,000 g), an equal volume of 2 × Lae-
mmli loading buffer was added to the lysate. Proteins
were separated by 10% SDS-PAGE and transferred to
Immun-blot PVDF membrane (Bio-Rad Laboratories,
Hercules, CA). The membrane was blocked and incubated
with primary antibody (see below). As secondary
antibodies, we used HRP-conjugated anti-rabbit, anti-
mouse IgG (Amersham Biosciences, Piscataway, NJ) or
anti-goat IgG in TBS-Tween for 1 hour and detected using
a chemiluminescent substrate (SuperSignal, Pierce Bio-
technology, Rockford, IL).
Antibodies
Antibodies against Kir6.1 subunits
Antibodies (NAF1) were raised against a peptide corre-
sponding to residues 20–31 of the Kir6.1 N-terminus
(ENLRKPRIRDRLP). There is a high degree of sequence
similarity in Kir6.1 subunits between species in this
region. We also raised a Kir6.1 antibody (CAF-1) to this
peptide in chickens. In each case, a C-terminal cysteine
was added for conjugation purposes. Peptides were syn-
thesized and the antibodies were generated commercially
(Quality Controlled Biochemicals, Hopkinton, MA). Each
of these antibodies were peptide affinity purified. There is
sequence similarity (81% identity) between this peptide
and the recently-identified human beta-V spectrin. We
tested for possible cross-reactivity of NAF-1 with beta-V
spectrin using antibodies generously provided by Dr Jon
Morrow (Yale University) and demonstrated that our anti-
bodies had no cross-reactivity with beta-V spectrin (please
see online Additional file 1). It should further be noted
that the antibody epitope has no similarity with mouse
beta-V spectrin (see UniGene Cluster Hs.198161).
Other anti-Kir6.1 antibodies that we attempted to use
with varying degrees of success included the 78A antibody
generated in the laboratory of Dr Tinker, which was raised
in rabbits against a peptide corresponding to amino acids
399–420 of rat Kir6.1 with a terminal cysteine added for
coupling purposes (RRNNSSLMVPKVQFMTPEGNQC)
and the goat anti-Kir6.1 R-14 or C-16 C-terminal antibod-
ies (sc-11224 and sc-11225; Santa Cruz Biotechnology,
Santa Cruz, CA). In our hands, the 78A and R-14 antibod-
ies failed to detect Kir6.1 protein in Western blotting of
cardiac membrane fractions and did not appear to stain
above background in immunohistochemistry assays (not
shown).
Antibodies against Kir6.2 subunits
We used a goat anti-Kir6.2 G-16 antibody (sc-11228;
Santa Cruz Biotechnology, Santa Cruz, CA) and an anti-
body (76A) developed in Dr Tinker's laboratory against a
peptide (DALTLASSRGPLRKRSC) corresponding to a pep-
tide within the Kir6.2 C-terminus (amino acids 357–372).
Antibodies against SUR subunits
We used a goat anti-SUR1 C-16 antibody (sc-5789; Santa
Cruz Biotechnology) developed to an epitope mapping at
the C-terminus and a goat anti-SUR2 C-15 C-terminal
antibody (sc-5793; Santa Cruz Biotechnology). This anti-
body was initially sold as a pan-SUR2 antibody and was
able to detect the SUR2A protein in Western blots of cell
lysates from Kir6.2/SUR2A transfected cells, although
with less sensitivity compared to SUR2B-transfected cells
(data not shown). Currently, the antibody with the same
catalog number is sold as being specific to SUR2B. We
have not tested recent batches of this antibody for isoform
specificity.
Other antibodies
Other antibodies used for immunolocalization included a
mouse monoclonal α-actin smooth muscle antibody pre-
conjugated to FITC (Clone 1A4; Sigma-Aldrich Corp, St.
Louis, MO) and a rat monoclonal antibody (clone 3C4;
BD Biosciences Pharmingen, San Diego, CA) raised
against ICAM-2 (CD102), which is a cell surface glycopro-
tein constitutively expressed on vascular endothelial cells.BMC Physiology 2005, 5:1 http://www.biomedcentral.com/1472-6793/5/1
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Secondary antibodies used included Cy3-conjugated don-
key anti-rabbit IgG, Cy3-conjgated donkey anti-chicken
IgY, Cy5-conjugated F(ab')2 fragment donkey anti-rat IgG
and a Cy3- or Cy5-conjugated donkey anti-goat IgG (all
from Jackson ImmunoResearch Laboratories Inc, West
Grove, PA).
List of abbreviations
Kir = Inward rectifying K+ channel family
SUR = Sulphonylurea receptor
KATP channel = ATP-sensitive K+ channel
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